Site-of-Care Shift for Physician-Administered Drug Therapies

Aaron Vandervelde and Eleanor Blalock write about the evolution of 340B Drug Discount Program utilization rates for breast cancer, rheumatoid arthritis, and multiple myeloma, as well as potential effects of a shift in site of care.

From the “Introduction”:

In June 2017, BRG professionals estimated that brand 340B drug sales represented 7.7 percent of the addressable market (i.e., brand, outpatient drugs). As part of that research, we studied three conditions commonly treated using brand drugs in the outpatient setting—breast cancer, rheumatoid arthritis, and multiple myeloma—and found in some cases that as much as 30 percent of 2015 Medicare Part B reimbursement was at 340B hospitals.

In this white paper, we analyze seven additional years of historical data to further explore how 340B Drug Discount Program utilization rates for these conditions evolved between 2008 and 2015. We also discuss the potential effects of this shift in site of care.